By the same authors

From the same journal

From the same journal

The Future of Precision Medicine: Potential Impacts for Health Technology Assessment

Research output: Contribution to journalArticle

Standard

The Future of Precision Medicine : Potential Impacts for Health Technology Assessment. / Love-Koh, James; Peel, Alison; Rejon-Parilla, Juan Carlos; Ennis, Kate; Lovett, Rosemary; Manca, Andrea; Chalkidou, Anastasia; Wood, Hannah; Taylor, Matthew.

In: Pharmacoeconomics, Vol. 36, No. 12, 21.11.2018, p. 1439-1451.

Research output: Contribution to journalArticle

Harvard

Love-Koh, J, Peel, A, Rejon-Parilla, JC, Ennis, K, Lovett, R, Manca, A, Chalkidou, A, Wood, H & Taylor, M 2018, 'The Future of Precision Medicine: Potential Impacts for Health Technology Assessment', Pharmacoeconomics, vol. 36, no. 12, pp. 1439-1451. https://doi.org/10.1007/s40273-018-0686-6

APA

Love-Koh, J., Peel, A., Rejon-Parilla, J. C., Ennis, K., Lovett, R., Manca, A., ... Taylor, M. (2018). The Future of Precision Medicine: Potential Impacts for Health Technology Assessment. Pharmacoeconomics, 36(12), 1439-1451. https://doi.org/10.1007/s40273-018-0686-6

Vancouver

Love-Koh J, Peel A, Rejon-Parilla JC, Ennis K, Lovett R, Manca A et al. The Future of Precision Medicine: Potential Impacts for Health Technology Assessment. Pharmacoeconomics. 2018 Nov 21;36(12):1439-1451. https://doi.org/10.1007/s40273-018-0686-6

Author

Love-Koh, James ; Peel, Alison ; Rejon-Parilla, Juan Carlos ; Ennis, Kate ; Lovett, Rosemary ; Manca, Andrea ; Chalkidou, Anastasia ; Wood, Hannah ; Taylor, Matthew. / The Future of Precision Medicine : Potential Impacts for Health Technology Assessment. In: Pharmacoeconomics. 2018 ; Vol. 36, No. 12. pp. 1439-1451.

Bibtex - Download

@article{e83acb0d01ac43d8a387a845809946f2,
title = "The Future of Precision Medicine: Potential Impacts for Health Technology Assessment",
abstract = "ObjectivePrecision medicine allows health care interventions to be tailored to groups of patients based on their disease susceptibility, diagnostic or prognostic information or treatment response. We analyse what developments are expected in precision medicine over the next decade and consider the implications for health technology assessment (HTA) agencies. MethodsWe perform a pragmatic review of the literature on the health economic challenges of precision medicine, and conduct interviews with representatives from HTA agencies, research councils and researchers from a variety of fields, including digital health, health informatics, health economics and primary care research. ResultsThree types of precision medicine are highlighted as likely to emerge in clinical practice and impact upon HTA agencies: complex algorithms, digital health applications and ‘omics’-based tests. Defining the scope of an evaluation, identifying and synthesizing the evidence and developing decision analytic models will more difficult when assessing more complex and uncertain treatment pathways. Stratification of patients will result in smaller subgroups, higher standard errors and greater decision uncertainty. Equity concerns may present in instances where biomarkers correlate with characteristics such as ethnicity, whilst fast-paced innovation may reduce the shelf-life of guidance and necessitate more frequent reviewing. DiscussionInnovation in precision medicine promises substantial benefits to patients, but will also change the way in which some health services are delivered and evaluated. As biomarker discovery accelerates and AI-based technologies emerge, the technical expertise and processes of HTA agencies will need to adapt if the objective of value for money is to be maintained.",
author = "James Love-Koh and Alison Peel and Rejon-Parilla, {Juan Carlos} and Kate Ennis and Rosemary Lovett and Andrea Manca and Anastasia Chalkidou and Hannah Wood and Matthew Taylor",
note = "{\circledC} The Author(s) 2018",
year = "2018",
month = "11",
day = "21",
doi = "10.1007/s40273-018-0686-6",
language = "English",
volume = "36",
pages = "1439--1451",
journal = "Pharmacoeconomics",
issn = "1170-7690",
publisher = "Adis International Ltd",
number = "12",

}

RIS (suitable for import to EndNote) - Download

TY - JOUR

T1 - The Future of Precision Medicine

T2 - Potential Impacts for Health Technology Assessment

AU - Love-Koh, James

AU - Peel, Alison

AU - Rejon-Parilla, Juan Carlos

AU - Ennis, Kate

AU - Lovett, Rosemary

AU - Manca, Andrea

AU - Chalkidou, Anastasia

AU - Wood, Hannah

AU - Taylor, Matthew

N1 - © The Author(s) 2018

PY - 2018/11/21

Y1 - 2018/11/21

N2 - ObjectivePrecision medicine allows health care interventions to be tailored to groups of patients based on their disease susceptibility, diagnostic or prognostic information or treatment response. We analyse what developments are expected in precision medicine over the next decade and consider the implications for health technology assessment (HTA) agencies. MethodsWe perform a pragmatic review of the literature on the health economic challenges of precision medicine, and conduct interviews with representatives from HTA agencies, research councils and researchers from a variety of fields, including digital health, health informatics, health economics and primary care research. ResultsThree types of precision medicine are highlighted as likely to emerge in clinical practice and impact upon HTA agencies: complex algorithms, digital health applications and ‘omics’-based tests. Defining the scope of an evaluation, identifying and synthesizing the evidence and developing decision analytic models will more difficult when assessing more complex and uncertain treatment pathways. Stratification of patients will result in smaller subgroups, higher standard errors and greater decision uncertainty. Equity concerns may present in instances where biomarkers correlate with characteristics such as ethnicity, whilst fast-paced innovation may reduce the shelf-life of guidance and necessitate more frequent reviewing. DiscussionInnovation in precision medicine promises substantial benefits to patients, but will also change the way in which some health services are delivered and evaluated. As biomarker discovery accelerates and AI-based technologies emerge, the technical expertise and processes of HTA agencies will need to adapt if the objective of value for money is to be maintained.

AB - ObjectivePrecision medicine allows health care interventions to be tailored to groups of patients based on their disease susceptibility, diagnostic or prognostic information or treatment response. We analyse what developments are expected in precision medicine over the next decade and consider the implications for health technology assessment (HTA) agencies. MethodsWe perform a pragmatic review of the literature on the health economic challenges of precision medicine, and conduct interviews with representatives from HTA agencies, research councils and researchers from a variety of fields, including digital health, health informatics, health economics and primary care research. ResultsThree types of precision medicine are highlighted as likely to emerge in clinical practice and impact upon HTA agencies: complex algorithms, digital health applications and ‘omics’-based tests. Defining the scope of an evaluation, identifying and synthesizing the evidence and developing decision analytic models will more difficult when assessing more complex and uncertain treatment pathways. Stratification of patients will result in smaller subgroups, higher standard errors and greater decision uncertainty. Equity concerns may present in instances where biomarkers correlate with characteristics such as ethnicity, whilst fast-paced innovation may reduce the shelf-life of guidance and necessitate more frequent reviewing. DiscussionInnovation in precision medicine promises substantial benefits to patients, but will also change the way in which some health services are delivered and evaluated. As biomarker discovery accelerates and AI-based technologies emerge, the technical expertise and processes of HTA agencies will need to adapt if the objective of value for money is to be maintained.

U2 - 10.1007/s40273-018-0686-6

DO - 10.1007/s40273-018-0686-6

M3 - Article

VL - 36

SP - 1439

EP - 1451

JO - Pharmacoeconomics

JF - Pharmacoeconomics

SN - 1170-7690

IS - 12

ER -